Health Guard plans dual listing to fund HPV vaccine fight
After a Beijing IPO last year, the loss-making biotech has also filed for a Hong Kong listing to better compete in the crowded market for HPV vaccines Key Takeaways: Beijing…
FAST NEWS: Zai Lab Acquires Exclusive Greater China License for Cervical Cancer Drug
The latest: Biotech drug maker Zai Lab Ltd. (9688.HK; ZLAB.US) announced on Tuesday that one of its subsidiaries has obtained an exclusive license to develop and commercialize Seagen Inc.’s (SGEN.US) cervical cancer…
RELATED ARTICLES
-
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK -
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
